Breaking News

You are here » Indian-Commodity  :  Commodities  :  Other Commodities  :  Nickel futures decline on subdued demand

10-Aug2018

Nickel futures decline on subdued demand

Nickel futures declined on MCX as participants cut down their bets amid subdued demand from alloy-makers and other consuming industries at the spot market.

The contract for August delivery was trading at Rs 951.10, down by 0.11% or Rs 1.00 from its previous closing of Rs 952.10. The open interest of the contract stood at 8319 lots.

The contract for September delivery was trading at Rs 956.40, down by 0.07% or Rs 0.70 from its previous closing of Rs 957.10. The open interest of the contract stood at 371 lots on MCX.

 


Related News

View all news

Nickel futures edge higher on improved demand

Nickel futures edged higher on MCX as participants enlarged their holdings on the back of improved demand from alloy-makers and other consuming industries at the spot market. The contract for October delivery......

Nickel futures edge higher on improved demand

Nickel futures edged higher on MCX as participants enlarged their holdings on the back of improved demand from alloy-makers and other consuming industries at the spot market. The contract for October delivery......

Coriander futures edge higher on improved demand

Coriander futures edged higher on NCDEX as participants built up fresh positions on the back of improved demand at the spot market. Further, tight supplies from major producing regions also fuelled the......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......